According to the research report titled ‘Global Liquid Biopsy Market 2021-2028’, available with Market Study Report, global liquid biopsy market is anticipated to register a healthy CAGR of 18.54% throughout 2021-2028.
 

High prevalence of cancer among the elderly population is a major factor driving the global liquid biopsy market growth. Further, technological innovations and growing demand for diagnostics centers are generating lucrative prospects for the business sphere.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3754634/
 

Speaking of the negatives, lack of skilled professionals along with high cost of liquid biopsy tests will limit the overall market growth over the estimated timeline.
 

Based on clinical application, the market is segmented into treatment monitoring, treatment selection, prognosis & reoccurrence monitoring, and diagnosis & screening. Speaking of therapeutic application, the marketplace is divided into non-oncology application, lung cancer, prostate cancer, breast cancer, colorectal cancer, melanoma cancer, and other types of cancer. Considering biomarker type, the market is categorized into protein, nucleic acid, extracellular vesicles and cells.
 

On the basis of analysis platform, global liquid biopsy market report emphasizes on NGS, PCR, microarray, and proteomics segments. Talking of analysis purpose, the industry is fragmented into early detection/screening, monitoring, therapy guidance, and diagnosis.
 

By product, the marketplace is segmented into circulating tumor DNA, cell-free DNA, circulating tumor cells, and extracellular vesicles and others. Moving on to industry verticals, the business space is divided into hospitals, physicians' office laboratories, and clinical diagnostic laboratories.
 

The geographical analysis of the industry extends to Latin America, Middle East & Africa, Asia Pacific, Europe, and North America. Expert analysts speculate that Asia Pacific market is reckoned to showcase substantial growth over the forecast timeline, attributable to presence of large patient pool, particularly in high populated countries like India and China. In addition, increase in healthcare spending and growing awareness regarding the use of liquid biopsy is augmenting the market remuneration scope in the APAC region.
 

Prominent players influencing the global liquid biopsy industry trends are Thermo Fisher Scientific Inc., Qiagen N.V., Personal Genome Diagnostics Inc., Natera Inc., Myriad Genetics Inc., Menarini Silicon Biosystems S.p.A, MDxHealth SA, Illumina Inc., Guardant Health Inc., Grail Inc., Foundation Medicine Inc., F. Hoffmann-La Roche AG, Bio-Rad Laboratories Inc., Biocept Inc., Becton Dickinson and Company, Angle plc, Agilent Technologies Inc., and Adaptive Biotechnologies Corp.